1. Home
  2. PCYO vs GLUE Comparison

PCYO vs GLUE Comparison

Compare PCYO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCYO
  • GLUE
  • Stock Information
  • Founded
  • PCYO 1976
  • GLUE 2019
  • Country
  • PCYO United States
  • GLUE United States
  • Employees
  • PCYO N/A
  • GLUE N/A
  • Industry
  • PCYO Water Supply
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCYO Utilities
  • GLUE Health Care
  • Exchange
  • PCYO Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • PCYO 248.0M
  • GLUE 276.2M
  • IPO Year
  • PCYO N/A
  • GLUE 2021
  • Fundamental
  • Price
  • PCYO $11.09
  • GLUE $4.87
  • Analyst Decision
  • PCYO
  • GLUE Buy
  • Analyst Count
  • PCYO 0
  • GLUE 2
  • Target Price
  • PCYO N/A
  • GLUE $13.50
  • AVG Volume (30 Days)
  • PCYO 40.5K
  • GLUE 422.1K
  • Earning Date
  • PCYO 07-09-2025
  • GLUE 08-07-2025
  • Dividend Yield
  • PCYO N/A
  • GLUE N/A
  • EPS Growth
  • PCYO 118.08
  • GLUE N/A
  • EPS
  • PCYO 0.59
  • GLUE 0.08
  • Revenue
  • PCYO $29,911,000.00
  • GLUE $159,487,000.00
  • Revenue This Year
  • PCYO N/A
  • GLUE $49.02
  • Revenue Next Year
  • PCYO N/A
  • GLUE N/A
  • P/E Ratio
  • PCYO $18.84
  • GLUE $62.85
  • Revenue Growth
  • PCYO 58.85
  • GLUE 14889.38
  • 52 Week Low
  • PCYO $9.10
  • GLUE $3.50
  • 52 Week High
  • PCYO $14.63
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • PCYO 63.99
  • GLUE 57.86
  • Support Level
  • PCYO $10.16
  • GLUE $4.42
  • Resistance Level
  • PCYO $11.16
  • GLUE $4.85
  • Average True Range (ATR)
  • PCYO 0.33
  • GLUE 0.27
  • MACD
  • PCYO 0.09
  • GLUE -0.00
  • Stochastic Oscillator
  • PCYO 93.97
  • GLUE 67.75

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: